Drug intelligence / Profile preview

ATT-03

Development stage: Preclinical
Lead developer: Attivare Therapeutics
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular (inferred As Standard For Vaccines; Not Explicitly Stated)

Overview

ATT-03 is an innovative malaria vaccine candidate developed by Attivare Therapeutics. The goal of ATT-03 is to enhance both the potency and durability of malaria vaccination, aiming to reduce the number of doses required for effective protection. As of May 2025, its highest global R&D status is preclinical. The vaccine leverages immunotherapy technology to potentially provide improved immune responses against malaria infection[1][2].

Beyond the preview

Go deeper on ATT-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATT-03.

Explore the full profile